NCT03492268View on ClinicalTrials.gov

Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2024

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

BCMA-CART

After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells

Trial Locations (1)

200241

Shanghai Bioray Laboratories INC., Shanghai

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT03492268 - Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma | Biotech Hunter | Biotech Hunter